Recent Headlines
Within Biotechnology
Industry’s First West Nile Virus Protease Assay Kits
While West Nile virus (WNV) has had significant outbreaks throughout the world since it was first identified, commercially available assay kits for the detection of WNV protease inhibitors had not been developed until now. With the SensoLyte™ series of WNV Protease Assay Kits AnaSpec, a... - May 17, 2007 - AnaSpec, EGT Group
Baxa Corporation Wins BMA Colorado 2007 Gold Key Award
Baxa Corporation's direct marketing campaign for the Rapid-Fill™ Automated Syringe Filler was awarded a Business Marketing Association Gold Key in the Colorado Chapter’s 2007 competition. Three messages: Safety is Automatic, Technology that Fits and Designed for Speed emphasized the key attributes that differentiate the Baxa product from competitive products and processes. - May 16, 2007 - Baxa Corporation
Clinical Trials in Russia - First Issue of SynRG Orange Paper
On April 25, 2007, the first issue of the Orange Paper – the first analytical review on market of clinical trials in Russia – was officially presented. The strategic goals of Synergy Research Group, a Russia-based emerging CRO, are formation of a civilized market of clinical trials in... - May 16, 2007 - Synergy Research Group
Futuristic Sleep Machine Now Reality
Those seeking improved sleep can switch on Sleep on Command™ device designed to enforce Delta rhythm sleep and the recovery that best occurs during deep, slow-wave, Delta-stage sleep. - May 08, 2007 - EarthPulse Tech, LLC
Baxa Corporation Signs Co-Marketing Agreement with CriticalPoint for Interactive Web-Based Training
Baxa Corporation announces its agreement with CriticalPoint LLC to co-market a Web-based sterile compounding curriculum authored by internationally recognized subject matter experts. This comprehensive, ACPE-approved program consists of 32 modules that meet USP Chapter 797’s competency assessment requirements. Modules are self-paced and part of CriticalPoint’s Learning Management System (LMS), offering access from any Web connection and providing administrative reporting for tracking. - May 07, 2007 - Baxa Corporation
2007-08 Bioscience Colorado Magazine Debuts at BIO International Convention in Boston
Colorado Bioscience Association is releasing the new edition of Bioscience Colorado Magazine at the 2007 BIO International Convention, May 6-9, at the Boston Convention & Exhibition Center. This year’s magazine has expanded to 80 pages and includes an updated directory of the Colorado Bioscience industry: Medical Device and Related Companies; Biotechnology, Pharmaceutical and Related Companies; Biofuels and Related Companies; Research & Education Institutions; Foundations; & Service Providers. - May 06, 2007 - Colorado BioScience Association
“Premature Infants Safer Because Of New Feeding System,” Case Study Now Accessible at PublicRelationsNewsroom.com
“Premature Infants Safer Because Of New Feeding System,” a case study from Premier, Inc., and its member hospitals, in collaboration with Baxa Corporation and VIASYS MedSystems, is now accessible at PublicRelationsNewsroom.com. According to the case, thanks to the collaboration, tiny infants receiving nutrition through feeding tubes now face far less danger from the risk of IV lines and feeding tubes being accidentally connected. - May 03, 2007 - Baxa Corporation
Training Makes a Difference: New Study Finds Farmer Production Costs Decreased, Farmer and Food Safety Increased
Farmers were able to reduce their costs of production, while more effectively controlling pests and better protecting themselves and their farms – all thanks to a practical training programme with farmers in rural China. “Responsible use of crop protection products increases food... - May 01, 2007 - CropLife Asia
Baxa Corporation Announces Enteral Syringes Now on Contract with AmeriNet, MedAssets, Novation and Premier Group Purchasing Organizations
Baxa Corporation announces its new syringes, designed for enteral feeding only, have been accepted on contract with key group purchasing organizations to facilitate hospital compliance with patient safety goals and to prevent wrong-route errors. Contracts for enteral syringes have been made between Baxa and these top US group purchasing organizations: AmeriNet, MedAssets, Novation and Premier. - April 30, 2007 - Baxa Corporation
Artificial Sun for Cell Culture Heating
The LAMBDA MINIFOR fermenter / bioreactor provides a new heating system for precise, fast and economic heating of the culture medium in fermentation and cell culture processes - April 29, 2007 - LAMBDA Laboratory Instruments
Baxa Corporation Features Pharmacy Automation and Dedicated Oral Dispensers at the Interphex 2007 Exhibition
Baxa Corporation is promoting its industry-leading products for automating pharmacy filling operations and safe dispensing of oral liquid medications at the annual Interphex Conference and Exhibition beginning today at the Jacob K. Javits Convention Center in New York City. The annual Interphex Conference brings together global companies serving the pharmaceutical and biotechnical industries. - April 24, 2007 - Baxa Corporation
Interleukin & Chemokine Antibodies – Two Types of Cytokine Antibodies
Interleukin-32 (IL-32), whose expression is increased following activation by IL-2, was initially identified as a transcript (NK4) selectively expressed in lymphocytes and NK cells.1 - April 18, 2007 - AnaSpec, EGT Group
Baxa Praises the UK’s NPSA Patient Safety Alert Advising Hospitals to Switch to Safer Oral/Enteral Syringes
The UK’s National Patient Safety Agency (NPSA) has released a Patient Safety Alert detailing the hazards of wrong-route administration and recommending immediate actions to ensure that oral/enteral medications cannot be administered through an intravenous connection. Hospitals can comply with the Patient Safety Alert immediately using the Exacta-Med® Oral/Enteral Dispensers from Baxa Ltd, Baxa Corporation’s UK subsidiary. - April 17, 2007 - Baxa Corporation
ABRF Poster Presents Comparison of Fluorescent Peptide Synthesis Methods
At the 2007 annual conference of the Association of Biomolecular Resource Facilities, AnaSpec presented a technical poster that compared the synthesis of a fluorescent peptide using two types of resins. The results of the poster indicated that the use of an unprotected resin was just as effective... - April 13, 2007 - AnaSpec, EGT Group
New Dye Solution for Far Red to NIR Imaging
Utilizing its proprietary HiLyte Fluor™ technology, AnaSpec has introduced dye solutions for far red to NIR imaging. AnaSpec’s HiLyte Fluor™ 647, HiLyte Fluor™ 680, and HiLyte Fluor™ 750 provide AnaSpec with a range of dyes that cover the spectrum. AnaSpec has also... - April 11, 2007 - AnaSpec, EGT Group
AnaSpec Introduces AnaTag™ Protein Labeling Kits
The labeling of proteins and antibodies with fluorescent dyes can play a crucial role in flow cytometry, immunohistochemistry and fluorescent in-situ hybridization techniques. Incorporating its high performance HiLyte Fluor™ dyes in a ready-to-use kit, AnaSpec has introduce its new line of... - April 04, 2007 - AnaSpec, EGT Group
Colorado Bioscience Association Launches Colorado Springs Chapter
The debut of the Colorado Springs Chapter of the Colorado Bioscience Association (CBSA) occurred yesterday at the University of Colorado at Colorado Springs (UCCS). The announcement is made by Denise Brown, CBSA Executive Director, who says UCCS Chancellor Pam Shockley hosted the chapter launch event. - March 29, 2007 - Colorado BioScience Association
AnaSpec Launches Optimized Website
In an effort to optimize the online experience of its customers, AnaSpec, a worldwide provider of integrated proteomics solutions, has moved its website to a faster, dedicated server. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, stated, “With the huge number of catalog... - March 28, 2007 - AnaSpec, EGT Group
Baxa Corporation Launches Educational Campaign Highlighting the Risks of Enteral Tubing Misconnections
Campaign for Baxa dedicated enteral systems focuses on educating providers on the risks, especially for neonatal patients, of wrong-route administration of non-IV fluids. While tubing misconnections can be deadly for any patient, neonates represent the highest risk population due to their small size and other health complications. The campaign launch closely follows the January 2007 release by the Joint Commission of their proposed 2008 National Patient Safety Goals (NPSGs) for comment. - March 21, 2007 - Baxa Corporation
Bio3 Research S.r.l., Milan – Italy, Has Been Granted by the Australian Patent Office a Patent in the Field of HMGB1
Bio3 Research S.r.l., Milan – Italy, has been granted by the Australian Patent Office a patent in the field of cardiovascular diseases related to HMGB1 over-expression and for the use of HMGB1 protein in connective tissue regeneration. - March 16, 2007 - Bio3 Research S.r.l.
Two Colorado Bioscience Legislative Initiatives Rank Among BIO’s Best Practices in the Nation
Two Colorado bioscience legislative initiatives are included in the national BIO “State Legislative Best Practices in Support of Bioscience Industry Development,” report issued late last year for state legislation promoting growth of bioscience clusters in 2005-06. Of the 23 standout initiatives, only two other states, California and Texas, had two projects highlighted. - March 14, 2007 - Colorado BioScience Association
Name Change: AnaSpec’s EnzoLyte is now SensoLyte™
AnaSpec, a worldwide provider of integrated proteomics solutions, announced today that the name of their flagship line of high-performance assay kits has been changed from EnzoLyte to SensoLyte™. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, noted, “The new name... - March 14, 2007 - AnaSpec, EGT Group
Xcelience Employs "CFS1200 Capsule Filling and Sealing Machine"
Xcelience's implementation of the CFS1200 will allow its formulation scientists the opportunity to accelerate the drug development timeframe. - March 13, 2007 - Xcelience, LLC
Xcelience Completes Successful QP Audit of Production Facility for European Market
Xcelience achives its third successful audit. - March 09, 2007 - Xcelience, LLC
The New Class of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Has One Clear Leader and Many Followers
Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field. - March 05, 2007 - La Merie Business Intelligence
Four Colorado Companies Participate at the 2007 Rocky Mountain Bioscience Venture Capital Meeting on the Mountain in Park City, Utah
Four Colorado-based companies are participating at the 2007 Rocky Mountain Bioscience Venture Capital Meeting on the Mountain, March 2-4, at the Park City (UT) Marriott. Dorsey & Whitney, lead sponsor of the event, hosts venture capitalists and area companies to learn and explore bioscience opportunities in the Rocky Mountain Region. Co-sponsors include UV Partners, vSpring Capital and Wasatch Venture Fund. - March 04, 2007 - Colorado BioScience Association
Xcelience Debuts its Innovative and Interactive Forum: XpertXchange™
XpertXchange will initiate dialogue between Xcelience scientists and drug development professionals. - March 02, 2007 - Xcelience, LLC
NWLS Transfers Marketing License Relating to Innovative Topical Drug Delivery to Atlan International
New Life Scientific, Inc. (OTCBB: NWLS), a company which specializes in the development of new biotechnology products and pharmaceuticals, announced today that it has transferred marketing rights to Atlan International(OTC: ATLI) of license agreement for two platform technologies (patent pending)... - February 27, 2007 - New Life Scientific, Inc.
Automated Internal Perfusion for the Port-a-Patch
Nanion Technologies introduces the Internal Perfusion System for the Port-a-Patch; a completely unique device for rapid, continuous and automated exchange of internal solutions during patch clamp recordings. Using the internal perfusion system, ion channels regulated by internal binding sites... - February 27, 2007 - Nanion Technologies GmbH
TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln
Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still No. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4%), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25%). - February 27, 2007 - La Merie Business Intelligence
Colorado Bioscience Association Showcases the State’s Most Promising Technologies
Colorado research institutions have begun reaping the rewards of legislation allocating state funds for bioscience research. HB 1360, sponsored by Representative Jim Reisberg (D-Greeley) and Senator Ron Tupa (D-Boulder), was signed into law by Governor Bill Owens last summer. $2 million in state funds was awarded to 27 bioscience proof of concept projects at six Colorado universities and research institutions. Initial reports are expected by the end of 2007. - February 23, 2007 - Colorado BioScience Association
Twenty-Four Colorado Companies Exhibited at the West Coast's Largest Design and Manufacturing Show, MD&M West
Twenty-four Colorado-based companies exhibited at the 23rd annual Medical Device & Manufacturing (MD&M) West show in Anaheim, CA, February 13-15. Colorado has a strong medical device manufacturing sector and was well represented at the MD&M trade show and conference. Several of Colorado’s regional economic development agencies were also in Anaheim assisting exhibiting companies and promoting the State of Colorado as a great place for doing business. - February 16, 2007 - Colorado BioScience Association
HiTIS - Life Science & Biotech Intelligence, A Global Life Sciences Industry Focused Competitive Intelligence Firm, Launched Skin Diseases Drug Development Weekly
HiTIS - life science & biotech intelligence, a global life sciences industry focused competitive intelligence firm, launched Skin Diseases Drug Development Weekly while the American Academy of Dermatology held its 65th annual meeting. - February 12, 2007 - HiTIS - Life Science & Biotech Intelligence
Dosing Convenience is Mandatory to Keep Pace in the Pipeline Race of GLP-1 Analogs for Type 2 Diabetes
The Business Intelligence firm La Merie S.L. reported today that major diabetes companies are trying to keep pace with Eli Lilly and Amylin Pharmaceutical in the field of GLP-1 analogs to treat type 2 diabetes. Lilly’s and Amylin’s first-in-class, but twice-daily product exenatide... - February 06, 2007 - La Merie Business Intelligence
Overview on 2006 Sales of Top 20 Biologics to Be Released on February 26
A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26. - February 05, 2007 - La Merie Business Intelligence
PharmaTrials Announces Expansion Plan into Asia
Pharma Trials International, Inc. a subsidiary of New Life Scientific, Inc. (OTCBB: NWLS), specializes in providing clinical trial services, market research, and services to enable pharmaceutical, biotech and medical device companies worldwide to conduct research and to obtain regulatory approval... - February 01, 2007 - New Life Scientific, Inc.
Baxa Announces 2007 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Baxa Corporation announces the training schedule for its professional Skills Training, Academics and Resources (STAR) Center for pharmacy and cleanroom skills training. The STAR Center, a premier facility designed for cleanroom and pharmacy practice demonstration, is located at the company’s world headquarters south of Denver, Colorado. Baxa Corporation built the STAR Center to provide professional education on pharmacy practice, cleanroom principles and compliance to regulatory requirements. - January 22, 2007 - Baxa Corporation
Feel The Pow(d)er - Precise and Reproducible Addition of Powdery Substances
LAMBDA Laboratory Instruments introduces a new digitally controlled, programmable powder dosing instrument. It allows precise, reproducible, automatic and continuous addition of powders, powdery and crystalline substances without a spoon. - January 20, 2007 - LAMBDA Laboratory Instruments
Baxa Releases New Safety-Focused Product Catalog
New catalog is magazine-catalog style and focuses on safety. Pharmacy safety enhancement has guided every Baxa innovation since their first product introduction more than 30 years ago. That product, the Exacta-Med® Oral Dispenser, has been the industry standard for safe administration of oral liquid medications ever since. - January 19, 2007 - Baxa Corporation
Baxa Corporation Signs Co-Marketing Agreement with VIASYS MedSystems for Specialty Enteral Feeding Products
Baxa Corporation announces its agreement with VIASYS MedSystems to co-market a dedicated enteral feeding system for neonates that reduces catheter misconnection errors. The first syringes designed only for enteral feeding, Baxa Exacta-Med Enteral Syringes are available individually packaged in 20, 35 and 60 mL sizes. - January 18, 2007 - Baxa Corporation
Xcelience Launches Drug Development Consulting Service
The launch of Xpert Consulting will provide supplemental services to assist clients. - January 17, 2007 - Xcelience, LLC
The Right Balance Drives the Field of PPAR Agonist R&D
A strongly growing market of now more than US$ 6 billion in 2006 for only two PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations. - January 12, 2007 - La Merie Business Intelligence
“Patient Safety and Peak Performance Through Pharmacy Training” from Baxa Corporation Focuses on Pharmaceutical Compounding Safety Concerns & Solutions
“Patient Safety and Peak Performance Through Pharmacy Training” from Baxa Corporation is now posted on PublicRelationsNewsroom.com for media and professional access. The article discusses the history of sterile compounding in pharmacy practice, current state, and the need for a purpose-built facility that provides practical, hands-on training in pharmacy preparation and regulatory compliance in order to achieve the level of patient safety and performance excellence required in today’s pharmacy. - December 28, 2006 - Baxa Corporation
ASCB Poster Presents Immunocapture Techniques for Improved MMP Assay
At the annual conference of the American Society for Cell Biology, AnaSpec presented a technical poster documenting improved technology for MMP detection assays. In a previous poster, AnaSpec documented the use of highly sensitive FRET-peptide substrates for MMP detection. The latest poster... - December 19, 2006 - AnaSpec, EGT Group
“Oral Medication Dispensers in Clinical Research,” a Technical Paper from Baxa Corporation, is Now Posted at PublicRelationsNewsroom.com
“Oral Medication Dispensers in Clinical Research,” a Technical Paper from Baxa Corporation is now posted for media and professional access on PublicRelationsNewsroom.com. Oral dispensers (syringes), long recognized as the safest and most accurate method to administer oral liquid medications, are especially valuable in clinical research where dosage accuracy has fundamental importance. - December 14, 2006 - Baxa Corporation
Fluorinated Building Blocks Produce Molecules with Enhanced Physiological Activities
The substitution of the fluorine in place of hydrogen in building blocks, such as amino acids, has produced molecules with enhanced physiological activities (1-2). Some of these are antibacterial, antihypertensive and antitumoral (3). One reason for the enhanced activity is that fluorine forms a... - December 12, 2006 - AnaSpec, EGT Group
Eric Kastango, MBA, RPh, is Now Profiled at the Expert Information for Journalists Website
Eric Kastango, president and CEO of Clinical IQ and frequent consultant to Baxa Corporation on hospital pharmacy safety issues is now profiled on the Expert Information For Journalists Web site – Expert411.com. Baxa Corp., a privately held company, is a leader in serving hospital pharmacy systems for handling, packaging and administering liquid medications from oral to multi-ingredient IV. Baxa is a registered medical device manufacturer with the FDA and has sales in more than 35 countries. - December 07, 2006 - Baxa Corporation
Baxa Corporation Introduces New Enteral Dispensers to Prevent Tubing Misconnections
Baxa Corporation announces new syringe-type dispensers designed for enteral feeding only to prevent wrong-route administration of non-IV fluids. The new Baxa Exacta-Med® Enteral Dispensers feature a unique dispenser tip that cannot connect to a luer needle or needleless IV system. - December 05, 2006 - Baxa Corporation
Baxa to Sponsor Exhibitor’s Theatre: The Perils and Pitfalls of Developing and Maintaining a Compliant Cleanroom
Colorado-based pharmacy products manufacturer, Baxa Corporation, is sponsoring a program at the annual American Society of Health-System Pharmacists’ Midyear Clinical Meeting in Anaheim. The speaker will discuss basic facility requirements for USP 797 compliance and the challenge of integrating primary engineering controls into facilities. - December 04, 2006 - Baxa Corporation
Functional Genetics, Inc. Announces Two Separate Awards from the United States Defense Threat Reduction Agency (DTRA) to Combat Viral Diseases
Functional Genetics, Inc. announced today that it has received two different awards from the United States Defense Threat Reduction Agency for the discovery and development of therapeutics for Ebola virus and other viral pathogens. "These awards from DTRA will greatly assist our mission of... - December 01, 2006 - Functional Genetics, Inc.